Journal article icon

Journal article

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial

Abstract:

Background: Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy in chemoprevention. Previous chemoprevention randomised controlled trials (RCTs) did not individually show benefit of HCQ against COVID-19 and, although meta-analysis did suggest clinical benefit, guidelines recommend against its use. Methods and findings: Healthy adult participants from the healthcare sett...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1371/journal.pmed.1004428

Authors


More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-6328-8748
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-5036-6583
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-3218-2166
More by this author
Role:
Author
ORCID:
0000-0002-6811-1124
More by this author
Institution:
University of Oxford
Role:
Author


More from this funder
Funder identifier:
https://ror.org/029chgv08


Publisher:
Public Library of Science
Journal:
PLoS Medicine More from this journal
Volume:
21
Issue:
9
Article number:
e1004428
Publication date:
2024-09-12
Acceptance date:
2024-06-14
DOI:
EISSN:
1549-1676
ISSN:
1549-1277


Language:
English
Source identifiers:
2257096
Deposit date:
2024-09-13
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP